Ionis Pharmaceuticals

IONS

Market cap $9.75B

Overview Fund Activity

61.17 USD

-0.15

0.24%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

61.00

-0.17

0.28%

1 day

-0.24%

5 days

-3.9%

1 month

40.85%

3 months

69.21%

6 months

78.34%

Year to date

76.33%

1 year

47.36%

5 years

19.26%

10 years

10.88%

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Employees: 927

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

117% more call options, than puts

Call options by funds: $65.2M | Put options by funds: $30M

100% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 12 (+6) [Q2]

40% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 58

33% more capital invested

Capital invested by funds: $5.01B [Q1] → $6.67B (+$1.67B) [Q2]

12% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 108

6% more funds holding

Funds holding: 339 [Q1] → 360 (+21) [Q2]

1.77% more ownership

Funds ownership: 104.33% [Q1] → 106.1% (+1.77%) [Q2]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$45

26% downside

Avg. target

$70

15% upside

High target

$96

57% upside

15 analyst ratings

12 positive

80%

2 neutral

13%

1 negative

7%

RBC Capital Luca Issi	$80	Outperform Maintained	4 Sep 2025
Citigroup David Lebowitz	$84	Buy Maintained	3 Sep 2025
Goldman Sachs Salveen Richter	$45	Sell Maintained	3 Sep 2025
BMO Capital Kostas Biliouris	$70	Outperform Upgraded	3 Sep 2025
Barclays Gena Wang	$78	Overweight Maintained	3 Sep 2025
Jefferies Akash Tewari	$96	Buy Maintained	2 Sep 2025
Needham Joseph Stringer	$70	Buy Maintained	2 Sep 2025
HC Wainwright & Co. Mitchell S. Kapoor	$95	Buy Maintained	2 Sep 2025
JP Morgan Jessica Fye	$49	Neutral Maintained	25 Aug 2025
Piper Sandler Allison Bratzel	$65	Overweight Maintained	22 Aug 2025
Wells Fargo Yanan Zhu	$82	Overweight Maintained	22 Aug 2025
UBS Esther Rajavelu	$46	Neutral Maintained	12 Aug 2025
Raymond James Gary Nachman	$64	Strong Buy Maintained	31 Jul 2025
Morgan Stanley Michael Ulz	$62	Overweight Upgraded	31 Jul 2025
HC Wainwright & Co. Mitchell Kapoor	$65	Buy Maintained	31 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 22 articles about IONS published over the past 30 days

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA) access to adaptive surfing, the event has expanded to include a myriad of adaptive experiences and will welcome additional communities impacted by neurological diseases, with more than 200 people from the Alexander diseas.

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)

After years of futility, Ionis' recent regulatory and clinical successes have spurred optimistic market attention. I review Q2/2025 earnings documents together with 09/04/2025 CEO Monia interview and CORE and CORE2 Topline Results transcript for current investment prospects. IONS stock has a boatload of recent and near term upcoming market moving catalysts.

Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)

Zacks Investment Research

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.'s IONS ION582 for Angelman syndrome (AS), a rare neurological disorder.

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), a rare neurological disease that often presents in infancy and is characterized by profound intellectual disability, impaired communication, motor impairment and debilitating seizures. “With no approved disease-modifying treatments available for people liv.

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 3:00 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Mitchell Kapoor - H.C.

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Ionis to host investors and analysts for Innovation Day 2025

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York. The agenda will feature presentations from members of the Ionis leadership team as well as a key thought leader in the treatment of severe hypertriglyceridemia, familial chylomicronemia syndrome and lipid disorders, Robert D. Fishberg, M.D., cardiologist with Atlantic Medical Group in Springfield, NJ, and assistant clinica.

Ionis to host investors and analysts for Innovation Day 2025

Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Okay. Thank you, everyone, for being here.

Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Zacks Investment Research

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

See News Rankings

Charts implemented using Lightweight Charts™